Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX induction regimen
Drug: Fluoropyrimidine (5-FU/LV or capecitabine)
Drug: Cetuximab
Drug: Trastuzumab
Drug: Bevacizumab
Drug: Pertuzumab
Drug: Vemurafenib
Drug: Atezolizumab
Drug: Cobimetinib
Drug: 5-FU/LV
Drug: Capecitabine

First Posted Date: 2014-11-14

Last Posted Date: 2024-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1044

Registration Number: NCT02291289

Locations: 🇦🇷
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología, Buenos Aires, Argentina
🇧🇪
Institut Jules Bordet X, Brussels, Belgium
🇧🇪
Hospital Erasme, Bruxelles, Belgium

and more 151 locations

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Trastuzumab Emtansine

First Posted Date: 2014-11-13

Last Posted Date: 2019-08-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT02289833

Locations: 🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇵🇱
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland
🇨🇭
CHUV; Departement d'Oncologie, Lausanne, Switzerland

and more 20 locations

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice

Completed

Conditions: Colorectal Cancer

First Posted Date: 2014-11-10

Last Posted Date: 2018-07-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 90

Registration Number: NCT02287597

Locations: 🇭🇷
Clinical Hospital Osijek; Dept For Oncology & Radiotherapy, Osijek, Croatia
🇭🇷
Uni Hospital Split; Oncology & Radiotherapy, Split, Croatia
🇭🇷
Uni Hospital For Tumours; Dept of Medical Oncology, Zagreb, Croatia

and more 1 locations

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2014-11-07

Last Posted Date: 2017-09-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 510

Registration Number: NCT02286362

Locations: 🇫🇷
CROM, Osny, France
🇫🇷
C H Du Pays D'Aix En Provence; Hopital De Jour, Aix En Provence, France
🇫🇷
Clinique Du Docteur Calabet; Cromg, Agen, France

and more 94 locations

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

Phase 1

Active, not recruiting

Conditions: Age-Related Macular Degeneration

Interventions: Biological: OpRegen

First Posted Date: 2014-11-07

Last Posted Date: 2025-01-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT02286089

A Study of RO6926496 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: RO6926496

First Posted Date: 2014-11-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 48

Registration Number: NCT02281786

Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer

Completed

Conditions: Gastric Cancer

First Posted Date: 2014-10-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 223

Registration Number: NCT02274376

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Device: Accu-Chek Smart Pix readout Device
Device: Accu-Chek Smart Pix Software

First Posted Date: 2014-10-20

Last Posted Date: 2017-11-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 414

Registration Number: NCT02268929

Observational Study of Pertuzumab Safety in Participants With Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Drug: Pertuzumab

First Posted Date: 2014-10-16

Last Posted Date: 2021-05-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1130

Registration Number: NCT02266173

Locations: 🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of

and more 34 locations

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Phase 3

Completed

Conditions: Pediatric Immuno-Tolerant Chronic Hepatitis B

Interventions: Drug: Entecavir
Drug: Lamivudine
Drug: Pegylated Interferon Alfa-2A

First Posted Date: 2014-10-13

Last Posted Date: 2020-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 62

Registration Number: NCT02263079

Locations: 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive, Bologna, Emilia-Romagna, Italy
🇩🇪
Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II, Essen, Germany

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy